Actively Recruiting
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Led by University Hospital, Grenoble · Updated on 2025-11-20
30
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
CONDITIONS
Official Title
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
- Patient with weight 63 32kg.
- With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
- Having given its written no objection to participate in the prospective phase of this project
You will not qualify if you...
- Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Grenoble Alpes
Grenoble, France, 38043
Actively Recruiting
Research Team
Y
Yvan CASPAR, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here